# Abacus Medicine Pharmaceuticals > ## Posts https://www.abacusmedicinepharmaceuticals.com/abacus-medicine-pharmaceuticals-to-accelerate-patient-access-across-europe/ – Abacus Medicine Pharmaceuticals to accelerate patient access across Europe: Today, Abacus Medicine Pharma Services is becoming Abacus Medicine Pharmaceuticals (AMP), a commercial-stage European pharmaceutical company. https://www.abacusmedicinepharmaceuticals.com/pharma-commercialization/ – Pharma commercialization strategies: Explore comprehensive strategies for successful pharma commercialization in Europe and ensure your product's success with expert insights. https://www.abacusmedicinepharmaceuticals.com/kol-engagement-strategy/ – KOL engagement strategy: With our KOL engagement strategy, we ensure that your product is recognised and understood by those who can recommend it or prescribe it. https://www.abacusmedicinepharmaceuticals.com/rwe-real-world-evidence/ – How real world evidence (RWE) impacts HTA submissions: Real world evidence (RWE) can provide an essential supplement to boost HTA submissions and accelerate clinical research. https://www.abacusmedicinepharmaceuticals.com/pharmacovigilance/ – Pharmacovigilance and regulatory affairs: Pharmacovigilance is crucial for ensuring the safety of orphan drugs, given the smaller trial sizes and ongoing need for monitoring. https://www.abacusmedicinepharmaceuticals.com/pharmaceutical-supply-chain/ – Pharmaceutical supply chain and its key components: Successful pharmaceutical supply chain management is fundamental to patient safety and product quality, when it comes to orphan drugs. https://www.abacusmedicinepharmaceuticals.com/drug-launch-benelux/ – Drug launch in Benelux: Benelux offers much potential, but they may need to surmount hurdles such as the region’s complex and lengthy reimbursement systems. https://www.abacusmedicinepharmaceuticals.com/access-to-medicine/ – Access to medicine in Europe’s small countries: How to improve health equity in Europe's small countries by removing the barriers to access medicine. https://www.abacusmedicinepharmaceuticals.com/drug-launch-nordics/ – Drug launch in the Nordics: What opportunities do the Nordic pharma markets offer, and what must industry players know to launch new medicines there? https://www.abacusmedicinepharmaceuticals.com/market-access-in-sweden/ – Navigating market access in Sweden: Pricing and reimbursement of pharmaceuticals is changing. Here’s what you need to know to navigate market access in Sweden. https://www.abacusmedicinepharmaceuticals.com/esg-in-pharma/ – ESG in pharma: meeting requirements in the Nordic region: Nordic healthcare pioneers ESG integration, offering pharma manufacturers a competitive advantage through regional developments. https://www.abacusmedicinepharmaceuticals.com/joint-procurement/ – The power of joint procurement in Benelux and the Nordics: Benelux and the Nordics are strengthening ties in Europe, combining procurement efforts to better access medicines. https://www.abacusmedicinepharmaceuticals.com/rare-disease-day/ – Rare Disease Day: raising awareness for a fairer future: Read our article on Rare Disease Day and why raising awareness is essential for a fairer future for rare disease patients. https://www.abacusmedicinepharmaceuticals.com/market-access-strategy-and-planning/ – Early planning for a successful market access in Europe: Developing a market access and pricing strategy early in the product lifecycle is crucial, especially in Europe's complex landscape. https://www.abacusmedicinepharmaceuticals.com/joint-hta-procedure/ – The EU joint HTA procedure: a gate or barrier for access? : The joint health technology assessment (HTA) procedure was a hot topic at the WODC-EU conference in Barcelona, and opinions were mixed. https://www.abacusmedicinepharmaceuticals.com/digital-medical-affairs/ – Digital medical affairs: benefits and challenges: In this article, we discuss the benefits and challenges of engaging medical professionals on digital channels. https://www.abacusmedicinepharmaceuticals.com/drug-commercialisation-outsourcing/ – How to determine when to outsource drug commercialisation: Partnership models are becoming increasingly important when launching a drug. When does it make sense to outsource? https://www.abacusmedicinepharmaceuticals.com/orphan-drugs-europe/ – The keys to launching orphan drugs in untapped markets in Europe: Learn how to successfully launch pharmaceuticals in some of Europe’s forgotten territories: Benelux and the Nordics. https://www.abacusmedicinepharmaceuticals.com/https-abacusmedicinepharmaservices-com-wp-content-uploads-2024-06-amps-cp0001-case-study-pdf/ – Multi market EU launch, promotion and distribution.: Learn more about how we helped a partner develop a prioritised market access strategy to launch a rare disease product in 10 EU countries. https://www.abacusmedicinepharmaceuticals.com/https-abacusmedicinepharmaservices-com-wp-content-uploads-2024-06-amps-cp0002-case-study-pdf/ – Simplifying medicine access and growth in the Nordics.: Read our case study on how we together with a number of partners identified a larger potential for sales growth and operational effectiveness ## Pages https://www.abacusmedicinepharmaceuticals.com/privacy-policy-for-marketing-communications/ – Privacy Policy for Marketing Communications: https://www.abacusmedicinepharmaceuticals.com/privacy-policy-for-marketing-communications-italian/ – Privacy Policy for Marketing Communications (Italian): At Abacus Medicine Pharma Services, we take your privacy and the security of your information very seriously. https://www.abacusmedicinepharmaceuticals.com/privacy-policy-for-marketing-communications-french/ – Privacy Policy for Marketing Communications (French): At Abacus Medicine Pharma Services, we take your privacy and the security of your information very seriously. https://www.abacusmedicinepharmaceuticals.com/privacy-policy-for-marketing-communications-spanish/ – Privacy Policy for Marketing Communications (Spanish): At Abacus Medicine Pharma Services, we take your privacy and the security of your information very seriously. https://www.abacusmedicinepharmaceuticals.com/privacy-policy-for-marketing-communications-german/ – Privacy Policy for Marketing Communications (German): At Abacus Medicine Pharma Services, we take your privacy and the security of your information very seriously. https://www.abacusmedicinepharmaceuticals.com/privacy-policy-for-marketing-communications-english/ – Privacy Policy for Marketing Communications (English): At Abacus Medicine Pharma Services, we take your privacy and the security of your information very seriously. https://www.abacusmedicinepharmaceuticals.com/login-customizer/ – Login Customizer: This page is used for Login Customizer plugin. It will not be visible to your readers. Do not delete it. https://www.abacusmedicinepharmaceuticals.com/terms-and-conditions/ – Terms and Conditions: The T&Cs constitute the sole record of the agreement between you and Abacus Medicine Pharma Services in relation to your use of the website. https://www.abacusmedicinepharmaceuticals.com/privacy-policy-and-cookie-policy/ – Privacy and Cookie Policy: At Abacus Medicine Pharma Services, we take your privacy and the security of your information very seriously. https://www.abacusmedicinepharmaceuticals.com/get-in-touch/ – Get in touch: Benefit from a complete end-to-end solution and take your product launch and commercialisation to the next level. https://www.abacusmedicinepharmaceuticals.com/contact-us/ – Contact us: See how your company could partner with Abacus Medicine Pharma Services and benefit from our commercialisation services. https://www.abacusmedicinepharmaceuticals.com/media/ – Media: Discover the latest corporate news from Abacus Medicine Pharma Services, along with press releases and company announcements. https://www.abacusmedicinepharmaceuticals.com/therapeutic-areas/ – Therapeutic Areas: Our expertise in these niche, narrow-field therapeutic areas drives innovation and faster drug launches across our European territories. https://www.abacusmedicinepharmaceuticals.com/portfolio/ – Portfolio: Our partnerships are focused on products indicated for metabolic, hematological, and neurological disorders. https://www.abacusmedicinepharmaceuticals.com/contact/ – Contact: Get in touch and see how your company could partner with Abacus Medicine Pharma Services and benefit from our commercialisation services. https://www.abacusmedicinepharmaceuticals.com/about/ – About: Abacus Medicine Pharma Services provides bespoke, end-to-end commercialisation solutions for innovators launching their assets in Europe https://www.abacusmedicinepharmaceuticals.com/ – Home: Providing bespoke end-to-end commercialisation solutions for rare disease innovators launching medicines in Europe. ## Media ## Landing Pages ## Floating Elements ## Solutions ## Therapeutic Areas https://www.abacusmedicinepharmaceuticals.com/therapeutic-area/adrenal-cortical-carcinoma/ – Adrenal Cortical Carcinoma: Adrenal Cortical Carcinoma (ACC) is a rare but aggressive type of cancer that originates in the adrenal cortex, the outer layer of the adrenal glands.The exact cause of adrenal cortical carcinoma is unknown. However, certain genetic syndromes, such as Li-Fraumeni… https://www.abacusmedicinepharmaceuticals.com/therapeutic-area/sickle-celldisease/ – Sickle Cell Disease: Sickle cell disease (SCD) is a genetic disorder characterised by the presence of abnormal haemoglobin, the protein responsible for carrying oxygen in red blood cells. This hereditary condition primarily affects individuals of African, Mediterranean, Middle Eastern, and Indian descent, but… https://www.abacusmedicinepharmaceuticals.com/therapeutic-area/alagille-syndrome/ – Alagille Syndrome: What is Alagille Syndrome? Alagille Syndrome (ALGS) is a rare genetic condition that usually appears in infancy or early childhood. It can affect several parts of the body, especially the liver and heart, but it may also involve the kidneys,… https://www.abacusmedicinepharmaceuticals.com/therapeutic-area/wilsons-disease/ – Wilson’s Disease: An overview of Wilson’s Disease, also known as hepatolenticular degeneration, a rare genetic disorder characterised by the accumulation of copper in the body’s tissues. Wilson’s Disease is inherited in an autosomal recessive manner, meaning that an individual must inherit two… https://www.abacusmedicinepharmaceuticals.com/therapeutic-area/bile-acid-synthesis-disorder/ – Bile Acid Synthesis Disorders: Bile acid synthesis disorders (BASDs) are a group of rare genetic metabolic disorders characterised by defects in the synthesis of bile acids. Bile acids are essential for digestion and absorption of dietary fats and fat-soluble vitamins. Disorders relating to them… https://www.abacusmedicinepharmaceuticals.com/therapeutic-area/niemann-picks-type-c/ – Niemann-Pick Type C: An overview of Niemann-Pick Type C, a rare inherited neurodegenerative disease characterised by impaired cholesterol trafficking within cells. Niemann-Pick Type C, also called NPC, is a rare neurodegenerative disease caused by mutations in either the NPC1 or NPC2 gene, which… https://www.abacusmedicinepharmaceuticals.com/therapeutic-area/cushing-syndrome/ – Cushing Syndrome: Cushing Syndrome, also known as hypercortisolism, is a disorder characterised by an excess of cortisol in the body. Cortisol is a steroid hormone produced by the adrenal glands, which are located on top of each kidney. While cortisol plays a… https://www.abacusmedicinepharmaceuticals.com/therapeutic-area/progressive-familial-intrahepatic-cholestasis/ – Progressive Familial Intrahepatic Cholestasis: Progressive Familial Intrahepatic Cholestasis (PFIC) refers to a group of rare genetic liver disorders characterised by impaired bile flow, leading to progressive liver damage and cholestasis, the accumulation of bile acids within liver cells. PFIC is primarily caused by genetic…